Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
From BeiGene, Ltd.
Via Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
From BeiGene, Ltd.
Via Business Wire
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200... 
Via Talk Markets
BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer
BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a... 
Via Benzinga
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)... 
Via Benzinga
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
From BeiGene, Ltd.
Via Business Wire
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Reports First Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
Two of AbbVie's most important assets could get a lot harder to sell. 
Via The Motley Fool
Topics Intellectual Property
A Heavy News Day And Crypto
Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today. 
Via Talk Markets
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against... 
Via Benzinga
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
Exceptions To A Low Period
This past week served as a negative period for my stock holdings, with a couple of exceptions. Here I discuss what those exceptions were and how they moved. 
Via Talk Markets
Currency Manipulation
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53. 
Via Talk Markets
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
From BeiGene, Ltd.
Via Business Wire
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
From BeiGene, Ltd.
Via Business Wire
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in... 
Via Talk Markets
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Heavy News Day - Cheats
US job losses were up 744,000 vs a forecast of 694,000. 
Via Talk Markets
BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study
BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring... 
Via Benzinga
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
From BeiGene, Ltd.
Via Business Wire
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
From BeiGene, Ltd.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.